ProQR Therapeutics initiated at Evercore ISI

ProQR Therapeutics initiated with an Outperform at Evercore ISI. Evercore ISI analyst Josh Schimmer initiated ProQR Therapeutics with an Outperform rating and $35 price target. The analyst believes the company’s recent clinical data for QR-110 for treatment of LCA-10 has transformed the outlook for the company, helping to “establish proof of concept for the lead program, it also helps de-risk the company’s broader platform.”
https://thefly.com/landingPageNews.php?id=2792279